{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T15:40:41Z","timestamp":1784302841254,"version":"3.55.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune system plays a central role in the pathogenesis of cancer and autoimmune diseases. An entire field has emerged to identify separate minor cell subpopulations carrying potential molecular targets or activation markers to study their prognostic role in disease progression and severity or predictive potential to use immunotherapy. However, the biomarker potential of minor populations is limited, as it does not take into account systemic interactions between populations of the immune system. A number of studies in the COVID era have shown that the certain balance between immune cell populations in donor\u2019s blood, called \u2018immunotype\u2019, can predict the outcome of treatment and the onset of a cytokine storm. This observation was extended to other diseases, including cancer and autoimmunity. It was shown that the immunotype can be used to diagnose both the presence of the disease itself, as well as its form or progression, to stratify patients in the risk groups and to predict the effectiveness of therapy. The most important advantages of immunotype-based diagnostics are its low invasiveness, the possibility of multiple biomaterial sampling, and the complexity of the analysis by the simultaneous assessment of blood cell composition and their functional activity. In this review, we summarize currently available studies of immunotypes and defined key subpopulations, their possible impact in diagnostics and personalization of the therapy in clinical routine practice in various diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1658970","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:45:05Z","timestamp":1756446305000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Diagnosis of cancer, autoimmune and infectious diseases and prediction of the therapy effectiveness based on the individual\u2019s immunotype"],"prefix":"10.3389","volume":"16","author":[{"given":"Dmitry V.","family":"Tabakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna A.","family":"Maznina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina A.","family":"Astakhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia E.","family":"Egorova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena N.","family":"Zakharova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga V.","family":"Glushkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina S.","family":"Petriaikina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry V.","family":"Svetlichnyy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Krupinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor P.","family":"Bogdanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir S.","family":"Yudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton A.","family":"Keskinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey M.","family":"Yudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Woroncow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika I.","family":"Skvortsova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel Yu","family":"Volchkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2016\/4273943","article-title":"The immune system in cancer pathogenesis: potential therapeutic approaches","volume":"2016","author":"Pandya","year":"2016","journal-title":"J Immunol Res"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA approval summary: pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30500-9","article-title":"Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study","volume":"7","author":"Leighl","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2023.2261248","article-title":"Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies","volume":"12","author":"Gide","year":"2023","journal-title":"OncoImmunology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23158656","article-title":"Activation markers on B and T cells and immune checkpoints in autoimmune rheumatic diseases","volume":"23","author":"Gerasimova","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2014.04.010","article-title":"Programmed death-1 pathway in cancer and autoimmunity","volume":"153","author":"Pedoeem","year":"2014","journal-title":"Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"New Engl J Med"},{"key":"B9","unstructured":"A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcutaneously in Patients With Plaque-type Psoriasis. Clinical trial registration NCT03337022. clinicaltrials.gov\n          \n          \n          \n          2020"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107612","article-title":"A review on applications of abatacept in systemic rheumatic diseases","volume":"96","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw288","article-title":"Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy","volume":"27","author":"Novotny","year":"2016","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp Mol Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-017-2072-1","article-title":"Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy","volume":"67","author":"Balatoni","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.ccell.2018.05.009","article-title":"\u2018Non-conventional inhibitory CD4+Foxp3\u2013PD-1hi T cells as a biomarker of immune checkpoint blockade activity\u2019","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13040930","article-title":"CD8+ T cell subsets as biomarkers for predicting checkpoint therapy outcomes in cancer immunotherapy","volume":"13","author":"Casalegno Gardu\u00f1o","year":"2025","journal-title":"Biomedicines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cells11111824","article-title":"Immune cell plasticity in inflammation: insights into description and regulation of immune cell phenotypes","volume":"11","author":"Margraf","year":"2022","journal-title":"Cells"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1042\/CS20220531","article-title":"M1\/M2 macrophages and their overlaps \u2013 myth or reality","volume":"137","author":"Strizova","year":"2023","journal-title":"Clin Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00377-3","article-title":"Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer","volume":"6","author":"Chen","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-019-09095-7","article-title":"\u2018Characterization of IL-17-producing Treg cells in type 2 diabetes patients\u2019","volume":"67","author":"Zhu","year":"2019","journal-title":"Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1258\/ebm.2011.011007","article-title":"Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity","volume":"236","author":"Jochems","year":"2011","journal-title":"Exp Biol Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.smim.2015.10.007","article-title":"Reprogramming away from the exhausted T cell state","volume":"28","author":"Karagiannis","year":"2016","journal-title":"Semin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22179414","article-title":"Peripheral blood-based biomarkers for immune checkpoint inhibitors","volume":"22","author":"An","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4377-1","article-title":"Regulatory T cell dysfunction in type 1 diabetes: what\u2019s broken and how can we fix it","volume":"60","author":"Hull","year":"2017","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1081889","article-title":"Single-cell RNA sequencing reveals the molecular features of peripheral blood immune cells in children, adults and centenarians","volume":"13","author":"Zhong","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.24715","article-title":"Cross-platform immunophenotyping of human peripheral blood mononuclear cells with four high-dimensional flow cytometry panels","volume":"103","author":"Heubeck","year":"2023","journal-title":"Cytomet Part A"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1705065114","article-title":"\u2018Continuous immunotypes describe human immune variation and predict diverse responses\u2019","volume":"114","author":"Kaczorowski","year":"2017","journal-title":"Proc Natl Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","article-title":"\u2018Variation in the human immune system is largely driven by non-heritable influences\u2019","volume":"160","author":"Brodin","year":"2015","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e13703","DOI":"10.1111\/acel.13703","article-title":"Identification of aging-associated immunotypes and immune stability as indicators of post-vaccination immune activation","volume":"21","author":"Cevirgel","year":"2022","journal-title":"Aging Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.29.24308098","article-title":"Baseline immunotypes and immune entropy are indicators of multiple vaccine responsiveness","author":"Cevirgel","year":"2024","journal-title":"medRxiv"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2017.00343","article-title":"T cell-mediated beta cell destruction: autoimmunity and alloimmunity in the context of type 1 diabetes","volume":"8","author":"Burrack","year":"2017","journal-title":"Front Endocrinol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.722979","article-title":"Natural killer cells as key mediators in type I diabetes immunopathology","volume":"12","author":"Gardner","year":"2021","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e170767","DOI":"10.1172\/jci.insight.170767","article-title":"Human immune phenotyping reveals accelerated aging in type 1 diabetes","volume":"8","author":"Shapiro","year":"2023","journal-title":"JCI Insight"},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13073-024-01300-z","article-title":"Systematic immune cell dysregulation and molecular subtypes revealed by single-cell RNA-seq of subjects with type 1 diabetes","volume":"16","author":"Honardoost","year":"2024","journal-title":"Genome Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1038\/s41467-024-47918-w","article-title":"Distinct cellular immune responses in children en route to type 1 diabetes with different first-appearing autoantibodies","volume":"15","author":"Starskaia","year":"2024","journal-title":"Nat Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04361.x","article-title":"Pathogenesis of kawasaki disease","volume":"164","author":"Takahashi","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1259353","article-title":"Integration of scRNA-Seq and bulk RNA-Seq uncover perturbed immune cell types and pathways of Kawasaki disease","volume":"14","author":"Cao","year":"2023","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s43556-024-00217-8","article-title":"Systemic lupus erythematosus: pathogenesis and targeted therapy","volume":"5","author":"Su","year":"2024","journal-title":"Mol Biomed"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf1970","article-title":"\u2018Single-cell RNA-seq reveals cell type\u2013specific molecular and genetic associations to lupus\u2019","volume":"376","author":"Perez","year":"2022","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.11.009","article-title":"The pathogenesis of rheumatoid arthritis","volume":"55","author":"Alivernini","year":"2022","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"key":"B43","doi-asserted-by":"publisher","first-page":"10058","DOI":"10.1038\/s41598-023-36999-0","article-title":"Peripheral blood cellular dynamics of rheumatoid arthritis treatment informs about efficacy of response to disease modifying drugs","volume":"13","author":"Hedman","year":"2023","journal-title":"Sci Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226228","article-title":"Peripheral blood immunophenotypic diversity in patients with rheumatoid arthritis and its impact on therapeutic responsiveness","volume":"84","author":"Kubo","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.11.015","article-title":"Peripheral immunotype correlates with minimal residual disease status and is modulated by immunomodulatory drugs in multiple myeloma","volume":"25","author":"Bhutani","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf5107","article-title":"LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade","volume":"13","author":"Shen","year":"2021","journal-title":"Sci Trans Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e23236","DOI":"10.1096\/fj.202301018R","article-title":"Advancement of anti-LAG -3 in cancer therapy","volume":"37","author":"Li","year":"2023","journal-title":"FASEB J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2101596","article-title":"Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines","volume":"11","author":"Hensler","year":"2022","journal-title":"OncoImmunology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41523-024-00638-2","article-title":"Peripheral immune cells in metastatic breast cancer patients display a systemic immunosuppressed signature consistent with chronic inflammation","volume":"10","author":"Chauhan","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ccell.2024.04.008","article-title":"\u2018Comprehensive peripheral blood immunoprofiling reveals five immunotypes with immunotherapy response characteristics in patients with cancer\u2019","volume":"42","author":"Dyikanov","year":"2024","journal-title":"Cancer Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8511","article-title":"\u2018Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications\u2019","volume":"369","author":"Mathew","year":"2020","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.55","article-title":"Longitudinal characterization of dysfunctional T cell-activation during human acute Ebola infection","volume":"7","author":"Agrati","year":"2016","journal-title":"Cell Death Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s13054-024-04990-4","article-title":"Integrated clustering of multiple immune marker trajectories reveals different immunotypes in severely injured patients","volume":"28","author":"Bodinier","year":"2024","journal-title":"Crit Care"},{"key":"B55","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/ckj\/sfac196","article-title":"Deep immune profiling of patients with renal impairment unveils distinct immunotypes associated with disease severity","volume":"16","author":"Wu","year":"2023","journal-title":"Clin Kidney J"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2023.103410","article-title":"Immune-mediated inflammatory diseases: Common and different pathogenic and clinical features","volume":"22","author":"Monteleone","year":"2023","journal-title":"Autoimmun Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ccell.2022.07.006","article-title":"Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes","volume":"40","author":"Zaitsev","year":"2022","journal-title":"Cancer Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.1038\/s41598-023-35300-7","article-title":"Investigating immune profile by CyTOF in individuals with long-standing type 1 diabetes","volume":"13","author":"Larsson","year":"2023","journal-title":"Sci Rep"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00580","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non\u2013small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-1312","article-title":"The landscape of immune microenvironments in racially diverse breast cancer patients","volume":"31","author":"Hamilton","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e41836","article-title":"Human immune system: Exploring diversity across individuals and populations","volume":"11","author":"Hoang Nguyen","year":"2025","journal-title":"Heliyon"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886736","article-title":"Functional impact of risk gene variants on the autoimmune responses in type 1 diabetes","volume":"13","author":"Gootjes","year":"2022","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2848","article-title":"Tumor-infiltrating and peripheral blood T-cell immunophenotypes predict early relapse in localized clear cell renal cell carcinoma","volume":"23","author":"Giraldo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17323","article-title":"Comparison of the predictive and prognostic capacities of neutrophil, lymphocyte and platelet counts and tumor-infiltrating lymphocytes in triple-negative breast cancer: preliminary results of the PERCEPTION study","volume":"44","author":"Giro","year":"2024","journal-title":"Anticancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v90i4.7057","article-title":"Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab","volume":"90","author":"Bersanelli","year":"2019","journal-title":"Acta Bio Med Atenei Parmensis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T05:45:07Z","timestamp":1756446307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2025.1658970"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658970","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"article-number":"1658970"}}